UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

CNS oncology, 2019-06, Vol.8 (2), p.CNS34

2019

Volltextzugriff (PDF)

Activity of pemetrexed in pre-clinical chordoma models and humans

Scientific reports, 2023-05, Vol.13 (1), p.7317-7317, Article 7317

2023

Volltextzugriff (PDF)

Characterization of molecular pathways for targeting therapy in glioblastoma

Chinese Clinical Oncology, 2020-12, Vol.9 (6), p.77-77

2020

Volltextzugriff (PDF)

Molecularly targeted treatment of recurrent anaplastic astrocytoma – a case report

Annals of clinical and translational neurology, 2021-09, Vol.8 (9), p.1913-1916

2021

Volltextzugriff (PDF)

Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2057-2057

2023

Volltextzugriff (PDF)

NCOG-33. GLIOBLASTOMA AND PARKINSONISM, IS DEPLETED DOPAMINE A PROTECTIVE SURVIVAL FACTOR? A CASE SERIES OF 3 GBM PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v221-v221

2023

Volltextzugriff (PDF)

QOL-28. THE LIVED EXPERIENCE OF PATIENTS WITH CHORDOMA – A RETROSPECTIVE CASE SERIES

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v255-v255

2023

Volltextzugriff (PDF)

EOLP-07. A REAL-WORLD INTEGRATED OUTPATIENT PALLIATIVE AND SUPPORTIVE CARE CLINIC IN A REGIONAL COMMUNITY NEURO-ONCOLOGY PRACTICE

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v114-v114

2023

Volltextzugriff (PDF)

QOL-14. INTEGRATING A TECHNOLOGY-ENABLED PLATFORM FOR PATIENT REPORTED OUTCOMES INTO A NEURO-ONCOLOGY PRACTICE

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v251-v251

2023

Volltextzugriff (PDF)

DDRE-09. MULTI-INSTITUTION RETROSPECTIVE EXPERIENCE WITH LENVATINIB FOR PROGRESSIVE MALIGNANT GLIOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi76-vi76

2021

Volltextzugriff (PDF)

INNV-23. CASE REPORT OF CISPLATIN + ETOPOSIDE FOR THE TREATMENT OF METASTATIC MALIGNANT MENINGIOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi110-vi110

2021

Volltextzugriff (PDF)

QLIF-16. CLINICAL AND SOCIAL CHALLENGES & OPPORTUNITIES IN TREATING GLIOBLASTOMA WITH TUMOR TREATMENT FIELDS, A CASE SERIES

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi204-vi204

2017

Volltextzugriff (PDF)

CTNI-15. PILOT STUDY OF HIGH-DOSE PEMETREXED FOR PROGRESSIVE CHORDOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v76-v76

2023

Volltextzugriff (PDF)

Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report

Neuro-oncology advances, 2024-01, Vol.6 (1), p.vdae110

2024

Volltextzugriff (PDF)

Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma

Clinical cancer research, 2024-01, Vol.30 (2), p.323

2024

Volltextzugriff (PDF)

The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14502-e14502

2020

Volltextzugriff (PDF)

CTNI-32. CASE SERIES OF BRAF INHIBITORS FOR THE TREATMENT OF BRAFV600E GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi66-vi66

2021

Volltextzugriff (PDF)

CTNI-46. PHASE I OPEN-LABEL, SINGLE-CENTER, DOSE ESCALATION STUDY (NCT02423525) OF PULSATILE AFATINIB IN PATIENTS WITH BRAIN CANCER

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi70-vi70

2021

Volltextzugriff (PDF)

BIOM-08. TARGETSELECTORTM CEREBROSPINAL FLUID (CSF) CIRCULATING TUMOR CELLS AND BIOMARKER ANALYSIS: IMPROVING SENSITIVITY AND TARGETED TREATMENT OPTIONS IN BREAST AND NSCLC CANCER PATIENTS WITH CNS INVOLVEMENT

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii3-ii3

2020

Volltextzugriff (PDF)

RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi218-vi219

2019

Volltextzugriff (PDF)

Response to OKN-007 and NAC in a Patient with Unilateral Hearing Loss and Chronic Tinnitus from Vestibular Schwannoma

The international tinnitus journal, 2023-06, Vol.27 (1)

2023

Volltextzugriff (PDF)

NIMG-63. OPTIMAL PATIENT AND FAMILY EDUCATION IS KEY TO IMPROVING THE EFFICACY OF TUMOR TREATING FIELDS PLUS CHEMOTHERAPY IN TREATMENT OF GBM

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi138-vi138

2016

Volltextzugriff (PDF)

A comprehensive initiative to optimize accrual to neuro oncology clinical trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18546-e18546

2018

Volltextzugriff (PDF)

ACTR-33. A PHASE I DOSE ESCALATION AND CENTRAL NERVOUS SYSTEM (CNS) PHARMACOKINETIC STUDY OF PULSATILE AFATINIB IN PATIENTS WITH BRAIN CANCER

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi7-vi8

2017

Volltextzugriff (PDF)

ACTR-62. A PHASE II STUDY OF TUMOR TREATING FIELDS (TTFIELDS) WITH TEMOZOLOMIDE IN PATIENTS WITH LOW-GRADE GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi14-vi14

2017

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(26)
Berichte
(2)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

Activity of pemetrexed in pre-clinical chordoma models and humans

Characterization of molecular pathways for targeting therapy in glioblastoma

Molecularly targeted treatment of recurrent anaplastic astrocytoma – a case report

Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm

NCOG-33. GLIOBLASTOMA AND PARKINSONISM, IS DEPLETED DOPAMINE A PROTECTIVE SURVIVAL FACTOR? A CASE SERIES OF 3 GBM PATIENTS

QOL-28. THE LIVED EXPERIENCE OF PATIENTS WITH CHORDOMA – A RETROSPECTIVE CASE SERIES

EOLP-07. A REAL-WORLD INTEGRATED OUTPATIENT PALLIATIVE AND SUPPORTIVE CARE CLINIC IN A REGIONAL COMMUNITY NEURO-ONCOLOGY PRACTICE

QOL-14. INTEGRATING A TECHNOLOGY-ENABLED PLATFORM FOR PATIENT REPORTED OUTCOMES INTO A NEURO-ONCOLOGY PRACTICE

DDRE-09. MULTI-INSTITUTION RETROSPECTIVE EXPERIENCE WITH LENVATINIB FOR PROGRESSIVE MALIGNANT GLIOMA

INNV-23. CASE REPORT OF CISPLATIN + ETOPOSIDE FOR THE TREATMENT OF METASTATIC MALIGNANT MENINGIOMA

QLIF-16. CLINICAL AND SOCIAL CHALLENGES & OPPORTUNITIES IN TREATING GLIOBLASTOMA WITH TUMOR TREATMENT FIELDS, A CASE SERIES

CTNI-15. PILOT STUDY OF HIGH-DOSE PEMETREXED FOR PROGRESSIVE CHORDOMA

Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report

Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma

The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement

CTNI-32. CASE SERIES OF BRAF INHIBITORS FOR THE TREATMENT OF BRAFV600E GLIOBLASTOMA

CTNI-46. PHASE I OPEN-LABEL, SINGLE-CENTER, DOSE ESCALATION STUDY (NCT02423525) OF PULSATILE AFATINIB IN PATIENTS WITH BRAIN CANCER

BIOM-08. TARGETSELECTORTM CEREBROSPINAL FLUID (CSF) CIRCULATING TUMOR CELLS AND BIOMARKER ANALYSIS: IMPROVING SENSITIVITY AND TARGETED TREATMENT OPTIONS IN BREAST AND NSCLC CANCER PATIENTS WITH CNS INVOLVEMENT

RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)

Response to OKN-007 and NAC in a Patient with Unilateral Hearing Loss and Chronic Tinnitus from Vestibular Schwannoma

NIMG-63. OPTIMAL PATIENT AND FAMILY EDUCATION IS KEY TO IMPROVING THE EFFICACY OF TUMOR TREATING FIELDS PLUS CHEMOTHERAPY IN TREATMENT OF GBM

A comprehensive initiative to optimize accrual to neuro oncology clinical trials

ACTR-33. A PHASE I DOSE ESCALATION AND CENTRAL NERVOUS SYSTEM (CNS) PHARMACOKINETIC STUDY OF PULSATILE AFATINIB IN PATIENTS WITH BRAIN CANCER

ACTR-62. A PHASE II STUDY OF TUMOR TREATING FIELDS (TTFIELDS) WITH TEMOZOLOMIDE IN PATIENTS WITH LOW-GRADE GLIOMAS

Suchergebnisse filtern